Skip to main content
Premium Trial:

Request an Annual Quote

Though Illumina s Q2 Revenues Increase 38 Percent, Stock Drops 14.7 Percent

NEW YORK, July 27 (GenomeWeb News) - Illumina yesterday reported increased revenues and losses for the second quarter of 2005.

 

The increased loss caused shares in the San Diego SNP-genotyping company to fall 14.68 percent, or $1.91, to $11.10 during mid-afternoon trading.

 

Revenues totaled $15.8 million for the quarter, a 38-percent increase over last year's $11.5 million for the same period.

 

The company's research and development expenses climbed to $7.3 million, up from $5.3 million during the year-ago period.

 

Illumina's net loss amounted to $18.5 million, or $.46 per share, up from $3.5 million, or $.10 per share, during last year's second quarter. This included a $15.8 million write-off of in-process research and development that Illlumina acquired with CyVera in April.

 

As of July 3, Illumina had $54.6 million in cash and investments.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.